A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Cedazuridine/decitabine (Primary) ; Decitabine
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Refractory anaemia; Refractory anaemia with excess of blasts; Sideroblastic anaemia
- Focus Pharmacokinetics; Registrational
- Acronyms ASCERTAIN
- Sponsors Astex Pharmaceuticals
- 23 Jan 2024 Results published in the Taiho Oncology Media Release
- 02 Jan 2024 According to a Taiho Oncology media release, data from this trial published in Lancet Haematology
- 12 Dec 2023 FInal results using DEC-C in an AML population (n=89), presented at the 65th American Society of Hematology Annual Meeting and Exposition